Seattle’s Infectious Disease Research Institute (IDRI) exited court-supervised receivership in 2022 and re-emerged as the Access to Advanced Health Institute (AAHI). The reset involved paying debts, reducing costs, changing leadership and governance, and narrowing the institute’s role: instead of trying to develop vaccines through manufacturing and commercialization, AAHI said it would focus on vaccine-enabling technologies and license them to biopharma companies earlier in development.
What happened to IDRI?
IDRI, a nonprofit research institute founded in 1993, entered voluntary receivership as it faced financial and operational strain. A receiver appointed under state authority, Shelly Crocker, helped restructure the organization. In 2022, a King County court approved its exit from receivership, and the institute took the name Access to Advanced Health Institute, or AAHI. GeekWire reported the transition on March 2, 2022.
The reported turnaround included settling debts owed to the landlord, vendors, and other entities, along with cost reductions and changes to the executive team and board. It was a reorganization of the institution, not simply a name change.
Why did the institute change its operating model?
IDRI had pursued a broad mission addressing diseases affecting low- and middle-income countries, including vaccine research. Its ambitions extended from early-stage research toward manufacturing, clinical trials, and getting products to market. CEO Corey Casper told GeekWire that this breadth was not sustainable for the nonprofit.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →#1 Best Overall
The new strategy concentrated on developing fundamental technologies that could help other organizations make vaccines, then licensing those technologies to biopharma companies at an earlier stage. Casper described the shift this way: “Rather than being the organization that was going to develop, manufacture, distribute and commercialize a vaccine for leprosy, now we see ourselves as an organization that makes the fundamental enabling technology for vaccines.”
| Operating question | IDRI’s former ambition | AAHI’s stated direction in 2022 |
|---|---|---|
| Mission and scope | Broad disease-focused research with ambitions spanning much of vaccine development. | Focus on fundamental technologies that enable vaccine development. |
| Development stage | Potentially carry programs from early research through later development. | License technologies to biopharma companies earlier in development. |
| Manufacturing and commercialization | Aspirations included manufacturing, distribution, and commercialization. | Shift away from taking vaccines through those stages itself. |
| Organization size | GeekWire reported 120 employees in 2019. | GeekWire reported about 60 employees in 2022. |
| Facility footprint | GeekWire reported the institute had occupied two and a half floors of its Seattle building before restructuring. | It occupied one floor in 2022, according to GeekWire. |
The staffing and floor-space figures describe the organization as reported in 2022; they do not establish its current size or footprint. Casper also framed the broader challenge for independent nonprofit research institutes as a need to be “strategic, lean, and productive” and to execute.
What happened to its research programs and partnerships?
The restructuring did not mean all research stopped. GeekWire’s March 2022 account described several projects and relationships underway at that time, but it does not establish their later status:
- A COVID-19 RNA vaccine candidate was designed for room-temperature stability and was expected then to enter clinical trials through an agreement with ImmunityBio.
- An RNA nasal-spray vaccine project for pandemic influenza was expanding with support from the U.S. Biomedical Advanced Research and Development Authority.
- The institute had licensing agreements concerning vaccine adjuvants.
- AAHI was developing or supporting satellite institutions in South Africa, Botswana, Kenya, Ghana, and Uganda.
The tuberculosis vaccine program had been mainly absorbed by Seattle Children’s Research Institute, according to the same report. GeekWire also reported philanthropic support from the Chan Soon-Shiong Family Foundation and that Patrick Soon-Shiong served on AAHI’s board at the time. In response to a question about the family relationship and conflicts of interest, an AAHI spokesperson described the institute as an independent Washington State nonprofit public charity operated for public benefit, and said it would share more about the relationship in the coming weeks.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteRank #3
What the 2022 account does—and does not—establish
The report documents a court-approved exit from receivership, a new name, cost-cutting, debt repayment, governance changes, and a narrower licensing-oriented strategy. It also gives a snapshot of selected programs and partnerships in March 2022. It does not establish AAHI’s present-day finances, leadership, staffing, clinical progress, or the current status of those projects and collaborations.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
